This Month in JNM ================= **Surface-enhanced Raman spectroscopy:** Andreou and colleagues provide perspective on in vivo imaging of cancer using this technique and biocompatible probes, highlighting recent advances and potential future applications. ***Page [1295](http://jnm.snmjournals.org/lookup/volpage/56/1295?iss=9)*** **Advancing apoptosis imaging:** Machulla offers an introduction to an article in this issue of *JNM* on a novel radiotracer that achieves its final form within apoptotic cells, allowing determination of tracer accumulation in tissue independently of blood flow. ***Page [1300](http://jnm.snmjournals.org/lookup/volpage/56/1300?iss=9)*** **Lumped constant estimation:** Keiding looks at challenges in estimation of the lumped constant proportionality factor in calculating hepatic glucose metabolic rate in 18F-FDG PET and previews a novel approach in an article in this issue of *JNM*. ***Page [1302](http://jnm.snmjournals.org/lookup/volpage/56/1302?iss=9)*** **Dosimetry for** **223****Ra-dichloride treatment:** Chittenden and colleagues report on the biodistribution, pharmacokinetics, absorbed doses, and safety of 2 sequential weight-based administrations of 223Ra-dichloride in patients with bone metastases from castration-refractory prostate cancer. ***Page [1304](http://jnm.snmjournals.org/lookup/volpage/56/1304?iss=9)*** **89****Zr-fresolimumab PET in recurrent glioma:** den Hollander and colleagues use PET to investigate uptake of the monoclonal antibody fresolimumab in recurrent high-grade gliomas and assess outcomes in patients treated with fresolimumab. ***Page [1310](http://jnm.snmjournals.org/lookup/volpage/56/1310?iss=9)*** **PET/CT and chemotherapy in IBC:** Champion and colleagues assess the value of 18F-FDG PET/CT imaging in predicting pathologic response to neoadjuvant chemotherapy and outcomes in inflammatory breast cancer. ***Page [1315](http://jnm.snmjournals.org/lookup/volpage/56/1315?iss=9)*** **18****F-FDG uptake in metastatic CRC:** Kawada and colleagues determine whether *KRAS* mutation status is associated with 18F-FDG accumulation in metastatic colorectal cancer and whether PET/CT imaging has the potential to predict *KRAS* status. ***Page [1322](http://jnm.snmjournals.org/lookup/volpage/56/1322?iss=9)*** **Posttreatment PET in Merkel cell carcinoma:** Byrne and colleagues explore the utility of 18F-FDG PET in restaging, response assessment, and management in patients after definitive treatment for Merkel cell carcinoma. ***Page [1328](http://jnm.snmjournals.org/lookup/volpage/56/1328?iss=9)*** **POEMS syndrome and PET:** Pan and colleagues report on the role of 18F-FDG PET in characterizing and evaluating patients with the rare paraneoplastic POEMS syndrome, involving polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. ***Page [1334](http://jnm.snmjournals.org/lookup/volpage/56/1334?iss=9)*** **SPECT/CT vs planar imaging in SLNs:** Jimenez-Heffernan and colleagues detail the results of an IAEA trial comparing SPECT/CT and planar lymphoscintigraphy in sentinel lymph node detection in malignancies with different lymphatic drainage, including breast cancer, melanoma, and pelvic tumors. ***Page [1338](http://jnm.snmjournals.org/lookup/volpage/56/1338?iss=9)*** **Cardiac PET and calcium imaging:** Brodov and colleagues determine whether the combined analysis of myocardial perfusion imaging and coronary artery calcium score in hybrid 82Rb PET/CT can improve diagnostic accuracy in detection of obstructive coronary artery disease. ***Page [1345](http://jnm.snmjournals.org/lookup/volpage/56/1345?iss=9)*** **Classification of amyloid PET data:** Carbonell and colleagues describe a statistical approach for automated classification of individuals with different levels of cognitive impairment into amyloid-low and amyloid-high groups using PET data from the Alzheimer Disease Neuroimaging Initiative study. ***Page [1351](http://jnm.snmjournals.org/lookup/volpage/56/1351?iss=9)*** **PET and τ quantification:** Kimura and colleagues report on a methodology for 11C-PBB3 PET quantification of τ pathology in a study group of individuals with and without Alzheimer disease. ***Page [1359](http://jnm.snmjournals.org/lookup/volpage/56/1359?iss=9)*** **PET/CT and hepatic glucose metabolism:** Trägårdh and colleagues investigate the feasibility of using dynamic 18F-FDG PET/CT to measure human hepatic glucose metabolism and determine an operational lumped constant for 18F-FDG by comparison with 3H-glucose measurements. ***Page [1366](http://jnm.snmjournals.org/lookup/volpage/56/1366?iss=9)*** **Dynamic** **11****C-phenytoin PET:** Mansor and colleagues assess optimal plasma kinetic models for quantification of 11C-phenytoin in human studies and discuss the potential for exploring pharmacoresistance in epilepsy and other diseases involving overexpression of P-glycoprotein. ***Page [1372](http://jnm.snmjournals.org/lookup/volpage/56/1372?iss=9)*** **Digital PET prototype:** Nguyen and colleagues report initial clinical experience, image quality, and diagnostic performance of a digital PET prototype scanner with time-of-flight technology. ***Page [1378](http://jnm.snmjournals.org/lookup/volpage/56/1378?iss=9)*** **123****I-CLINDE in GBMs:** Jensen and colleagues compare translocator protein SPECT imaging using this iodine-labeled tracer with amino acid transport 18F-FET imaging and gadolinium-enhanced MR imaging in predicting progression of glioblastoma multiforme at follow-up. ***Page [1386](http://jnm.snmjournals.org/lookup/volpage/56/1386?iss=9)*** **Pediatric bone scan dose optimization:** Ayres and colleagues look at overall image quality in pediatric bone scintigraphy acquired with lower administered activities as recommended by North American Consensus Guidelines and the European Association of Nuclear Medicine. ***Page [1391](http://jnm.snmjournals.org/lookup/volpage/56/1391?iss=9)*** **Small-bowel and colon motility studies:** Maurer provides the second of 2 educational overviews of methodology, challenges, and evolving standards for gastrointestinal transit scintigraphy, including small-bowel, colon, and whole-gut motility studies. ***Page [1395](http://jnm.snmjournals.org/lookup/volpage/56/1395?iss=9)*** **PSMA Auger radiopharmaceutical therapy:** Kiess and colleagues describe the use of a highly specific small molecule targeting the prostate-specific membrane antigen to deliver 125I to prostate cancer cells, with promise for treatment of micrometastases. ***Page [1401](http://jnm.snmjournals.org/lookup/volpage/56/1401?iss=9)*** **Multimodal PVC in bone PET/CT:** Grecchi and colleagues detail the development of a novel multimodal partial volume correction approach for more accurate lesion characterization in 18F-fluoride PET/CT bone metastasis studies. ***Page [1408](http://jnm.snmjournals.org/lookup/volpage/56/1408?iss=9)*** **Kinetic analysis of** **18****F-C-SNAT:** Palner and colleagues examine the in vivo pharmacokinetics of this apoptosis imaging tracer through PET imaging and kinetic modeling in a preclinical mouse model of tumor response to systemic anticancer chemotherapy. ***Page [1415](http://jnm.snmjournals.org/lookup/volpage/56/1415?iss=9)*** **Diabody pretargeting:** van Duijnhoven and colleagues develop and evaluate a pretargeting strategy using click chemistry to reduce kidney uptake and avoid unwanted radiation toxicity in radioimmunotherapy and associated immune-PET/SPECT imaging. ***Page [1422](http://jnm.snmjournals.org/lookup/volpage/56/1422?iss=9)*** **Retention kinetics of** **18****F-LMI1195:** Werner and colleagues explore the neural uptake of this PET tracer designed for assessment of sympathetic innervation of the heart and compare this with the kinetics of 11C-hydroxyephedrine and 123I-MIBG. ***Page [1429](http://jnm.snmjournals.org/lookup/volpage/56/1429?iss=9)*** **18****F-trimeric sulfonamides:** Lau and colleagues describe the process of synthesizing four 18F-labeled sulfonamide derivatives and evaluate their potential for PET imaging of carbonic anhydrase IX expression. ***Page [1434](http://jnm.snmjournals.org/lookup/volpage/56/1434?iss=9)*** **Evaluation of Auger electron emitters:** Falzone and colleagues characterize the therapeutic utility and potential adverse characteristics of 12 Auger-emitting radionuclides with theranostic potential. ***Page [1441](http://jnm.snmjournals.org/lookup/volpage/56/1441?iss=9)*** **Phantom and clinical evaluation of Q.Clear:** Teoh and colleagues determine the optimum penalization factor for clinical use of this commercial Bayesian penalized-likelihood reconstruction algorithm for PET and compare it with standard PET reconstructions. ***Page [1447](http://jnm.snmjournals.org/lookup/volpage/56/1447?iss=9)*** **Change in NIST** **18****F standard:** Zimmerman and colleagues update relative response ratios for a 68Ge solid epoxy mock syringe source used in activity calibrators, per recent changes in National Institute of Standards and Technology activity standards for 18F. ***Page [1453](http://jnm.snmjournals.org/lookup/volpage/56/1453?iss=9)*** **β-radioluminescence imaging:** King and colleagues propose a new modality that incorporates a scintillator with a γ rejection strategy for imaging β particles and perform comparative studies with this technology and Cerenkov luminescence imaging. ***Page [1458](http://jnm.snmjournals.org/lookup/volpage/56/1458?iss=9)*** * © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.